Long-Term Outcome and MGMT as a Predictive Marker in 24 Patients With Atypical Pituitary Adenomas and Pituitary Carcinomas Given Treatment With Temozolomide

Daniel Bengtsson, Henrik Daa Schrøder, Marianne Andersen, Dominique Maiter, Katarina Berinder, Ulla Feldt Rasmussen, Åse Krogh Rasmussen, Gudmundur Johannsson, Charlotte Hoybye, Aart Jan van der Lely, Maria Petersson, Oskar Ragnarsson, Pia Burman
  • The Journal of Clinical Endocrinology & Metabolism, April 2015, Endocrine Society
  • DOI: 10.1210/jc.2014-4350

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication


The following have contributed to this page: Professor Ulla Feldt-Rasmussen, Professor Gudmundur Johannsson, and Daniel Bengtsson